Glenmark Pharma’s arm launches Trandolapril, Verapamil Hydrochloride tablets in US

26 Feb 2015 Evaluate

Glenmark Generics Inc (GGI), a step down subsidiary of Glenmark Pharmaceuticals has received US market approval and introduction of Trandolapril & Verapamil Hydrochloride (HCI) Extended Release Tablets, the generic equivalent of AbbVie, Inc.’s TARKA.

TARKA is indicated for the treatment of hypertension. According to IMS Health sales data for the 12 month period ending December 2014, TARKA achieved annual sales of approximately $23.5 million.

Glenmark will commence distribution of Trandolapril & Verapamil HCI Tablets immediately, which will be available in 1mg/240mg, 2mg/180mg, 2mg/240mg and 4mg/240mg strengths.

Glenmark’s current portfolio consists of 95 products authorized for distribution in the US marketplace and 74 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×